Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$1.5 - $2.33 $24,000 - $37,280
16,000 New
16,000 $24,000
Q2 2022

Jul 29, 2022

SELL
$0.81 - $1.34 $62,075 - $102,693
-76,637 Closed
0 $0
Q1 2022

May 05, 2022

SELL
$1.23 - $1.95 $94,341 - $149,565
-76,700 Reduced 50.02%
76,637 $100,000
Q4 2021

Jan 21, 2022

SELL
$1.74 - $2.4 $124,328 - $171,487
-71,453 Reduced 31.79%
153,337 $269,000
Q3 2021

Nov 08, 2021

SELL
$2.08 - $3.6 $1,098 - $1,900
-528 Reduced 0.23%
224,790 $487,000
Q2 2021

Aug 04, 2021

BUY
$3.36 - $10.56 $487,505 - $1.53 Million
145,091 Added 180.85%
225,318 $787,000
Q4 2020

Feb 08, 2021

SELL
$9.84 - $14.26 $370,318 - $536,660
-37,634 Reduced 31.93%
80,227 $869,000
Q3 2020

Nov 09, 2020

BUY
$10.3 - $21.64 $776,990 - $1.63 Million
75,436 Added 177.81%
117,861 $1.21 Million
Q2 2020

Aug 05, 2020

BUY
$8.53 - $25.64 $107,580 - $323,371
12,612 Added 42.3%
42,425 $883,000
Q1 2020

May 06, 2020

BUY
$7.98 - $16.32 $237,907 - $486,548
29,813 New
29,813 $291,000
Q3 2018

Oct 26, 2018

SELL
$4.5 - $7.6 $93,150 - $157,320
-20,700 Closed
0 $0
Q2 2018

Aug 08, 2018

SELL
$5.3 - $6.9 $10,600 - $13,800
-2,000 Reduced 8.81%
20,700 $110,000
Q1 2018

May 11, 2018

SELL
$3.65 - $7.95 $112,993 - $246,108
-30,957 Reduced 57.69%
22,700 $132,000
Q4 2017

Feb 06, 2018

SELL
$2.85 - $3.95 $35,163 - $48,735
-12,338 Reduced 18.7%
53,657 $193,000
Q3 2017

Nov 07, 2017

BUY
$2.45 - $3.65 $161,687 - $240,881
65,995
65,995 $241,000

Others Institutions Holding ADVM

About Adverum Biotechnologies, Inc.


  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $471M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.